➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Last Updated: October 28, 2021

DrugPatentWatch Database Preview

Claims for Patent: 10,053,504

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,053,504
Title:SPARC binding ScFvs
Abstract: The invention provides compositions comprising SPARC binding ScFv and its use.
Inventor(s): Trieu; Vuong (Agoura Hills, CA)
Assignee: ABRAXIS BIOSCIENCE, LLC (Los Angeles, CA)
Application Number:15/132,647
Patent Claims:1. A method for treating cancer differentially expressing SPARC in a mammalian subject comprising: (a) preparing a composition comprising one or more SPARC binding ScFvs whose amino acid sequences consist of SEQ ID NOS: 113-116, wherein each of the one or more ScFvs specifically binds SPARC and is conjugated to: i) a cytotoxic moiety that is effective to inhibit the proliferation and/or survival of cancer cells in the mammalian subject, or ii) an antibody fragment comprising a functional antibody Fc domain capable of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC), and wherein the composition, optionally, further comprises a pharmaceutically acceptable carrier; and (b) administering to a mammalian subject a therapeutically effective amount of the composition.

2. The method of claim 1, wherein the functional antibody Fc domain comprises SEQ ID NO: 118.

3. The method of claim 1, wherein the cytotoxic moiety is selected from the group consisting of a radionuclide, adriamycin, ansamycin antibiotics, asparaginase, bleomycin, busulphan, cisplatin, carboplatin, carmustine, capecitabine, chlorambucil, cytarabine, cyclophosphamide, camptothecin, dacarbazine, dactinomycin, daunorubicin, dexrazoxane, docetaxel, doxorubicin, etoposide, epothilones, floxuridine, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, mercaptopurine, melphalan, methotrexate, rapamycin (sirolimus), mitomycin, mitotane, mitoxantrone, nitrosourea, paclitaxel, pamidronate, pentostatin, plicamycin, procarbazine, rituximab, streptozocin, teniposide, thioguanine, thiotepa, taxanes, vinblastine, vincristine, vinorelbine, combretastatins, discodermolides, transplatinum, 5-fluorouracil, genistein, Truncated Tissue Factor ("tTF"), Tumor Necrosis Factor ("TNF"), Scaffold Matrix Attachment Region binding protein 1 ("Smar1") derived p44 peptide, interferon, TNF-Related Apoptosis-Inducing Ligand ("TRAIL"), Second-Mitochondria Activator of Caspases ("Smac"), Von Hipel-Lindau tumor suppressor ("VHL") procaspase, caspase, IL-2, a non-Fc domain antibody fragment, and combinations thereof.

4. The method of claim 1, wherein the mammalian subject is a human.

Details for Patent 10,053,504

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 1978-01-10 ⤷  Free Forever Trial 2028-12-05
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Free Forever Trial 2028-12-05
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 2017-06-22 ⤷  Free Forever Trial 2028-12-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.